International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab

BACKGROUND AND OBJECTIVES: Neuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG)–seropositive NMOSD (eculizumab, inebilizumab, and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Friedemann, Marignier, Romain, Palace, Jacqueline, Arrambide, Georgina, Asgari, Nasrin, Bennett, Jeffrey L., Cree, Bruce Anthony Campbell, De Sèze, Jérôme, Fujihara, Kazuo, Kim, Ho Jin, Hornby, Rebecca, Huda, Saif, Kissani, Najib, Kleiter, Ingo, Kuwabara, Satoshi, Lana-Peixoto, Marco, Law, Lisa, Leite, M. Isabel, Pandit, Lekha, Pittock, Sean J., Quan, Chao, Ramanathan, Sudarshini, Rotstein, Dalia, Saiz, Albert, Sato, Douglas Kazutoshi, Vaknin-Dembinsky, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231913/
https://www.ncbi.nlm.nih.gov/pubmed/37258412
http://dx.doi.org/10.1212/NXI.0000000000200124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231913/
https://www.ncbi.nlm.nih.gov/pubmed/37258412
http://dx.doi.org/10.1212/NXI.0000000000200124

Ejemplares similares